Promis Neurosciences (PMN) to Release Earnings on Monday

Promis Neurosciences (NASDAQ:PMN) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Promis Neurosciences to post earnings of ($4.22) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 9:30 AM ET.

Promis Neurosciences Stock Down 3.3%

Shares of NASDAQ:PMN opened at $17.60 on Monday. The company has a market capitalization of $37.88 million, a P/E ratio of -0.93 and a beta of -0.23. Promis Neurosciences has a 52-week low of $6.27 and a 52-week high of $39.75. The stock’s fifty day simple moving average is $15.59 and its 200-day simple moving average is $11.79.

Insider Buying and Selling

In related news, major shareholder Abg Management Ltd. purchased 700,741 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was purchased at an average price of $12.13 per share, with a total value of $8,499,988.33. Following the completion of the transaction, the insider owned 943,090 shares of the company’s stock, valued at approximately $11,439,681.70. This trade represents a 289.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanne Kaplan purchased 1,629 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were bought at an average cost of $15.35 per share, for a total transaction of $25,005.15. Following the purchase, the insider owned 3,941 shares of the company’s stock, valued at $60,494.35. This trade represents a 70.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 705,370 shares of company stock valued at $8,595,523. Insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Promis Neurosciences stock. Armistice Capital LLC grew its holdings in shares of Promis Neurosciences (NASDAQ:PMN) by 39.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,974,518 shares of the company’s stock after buying an additional 836,622 shares during the quarter. Armistice Capital LLC owned 5.53% of Promis Neurosciences worth $1,264,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 50.13% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on PMN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Promis Neurosciences in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Promis Neurosciences to a “strong sell” rating in a report on Saturday, February 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective (up from $4.00) on shares of Promis Neurosciences in a research report on Monday, December 1st. Finally, Guggenheim reduced their price objective on shares of Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.67.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.